Randomized, Double-Blind, Placebo-Controlled, With PHX1149 in Patients With Type 2 Diabetes Mellitus
Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
This will be a 4-week, multicenter, randomized, double-blind, parallel group,
placebo-controlled, safety, tolerability, and efficacy study. Patients will be screened and
be on one of three doses of PHX1149 (a new drug candidate for the treatment of Type 2
diabetes ) or placebo. The drug is a "DPP4 inhibitor"